Final-cohort milestone: The Australian oncology study of the Hemopurifier has advanced into its third and final dosing cohort, with full-trial data readout now the next major catalyst for the company's forward outlook. Strategic positioning: Aethlon Medical holds FDA Breakthrough Device designation for both cancer and life-threatening viral indications, supporting a differentiated blood-purification platform with limited direct competition.
Autonomix Medical, Inc. ( AMIX ) is a development-stage medical device company focused on sensing and treating disorders of the peripheral nervous system. The company is pre-revenue and clinical-stage, meaning it has not yet generated product sales and relies on external financing to fund operations.
The company's forward trajectory hinges on commercial execution of its LIBERTY Endovascular Robotic System, with a Full Market Release targeted around the Society of Interventional Radiology (SIR) conference in April 2026. LIBERTY's single-use, remotely operated design eliminates the capital-equipment and service burden of traditional robotic systems, positioning it as a potentially scalable, consumable-driven model.
MBOT is the Nasdaq ticker for Microbot Medical Inc., a commercial-stage medical device company focused on endovascular robotics. The company's flagship product, the LIBERTY Endovascular Robotic System, is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
AVR is the Nasdaq ticker for Anteris Technologies Global Corp., a development-stage medical device company focused on structural heart disease. The company's lead product is the DurAVR Transcatheter Heart Valve (THV) System, a "biomimetic" valve designed to treat severe aortic stenosis.
Product pipeline is the primary near-term catalyst: InMode is rolling out two new platforms per year, including a Pico laser and a combined Morpheus8/Erbium YAG device, while pursuing expanded U.S. Food and Drug Administration (FDA) clearance for its Envision ophthalmology platform. Strategic positioning remains anchored in RF technology: The company is a leading provider of minimally invasive, radiofrequency (RF)-based aesthetic devices such as Morpheus8, supported by a large global installed base and a growing consumables and services revenue stream.
INMD is the Nasdaq ticker for InMode Ltd., an Israeli medical technology company that develops and sells minimally invasive and non-invasive aesthetic devices. The company's proprietary radio frequency (RF) technology is used across plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
Co-Diagnostics shares declined roughly 76% over the last 30 days, falling from about $1.07 to around $0.25 as liquidity concerns outweighed a headline earnings beat. Third-quarter 2026 results topped consensus estimates, yet the stock continued to slide amid a thin cash balance and new financing arrangements.
AMIX shares have fallen roughly 55% over the last 30 days, sliding from about $3.01 to near $1.36, extending a much deeper multi-month downtrend. The decline has unfolded despite a series of positive milestones, including FDA pre-submission feedback supporting a 510(k) pathway and newly issued patents in the U.S., Europe, and Canada.
Neuronetics (STIM) shares declined roughly 26% over the trailing 30 days, falling from about $1.99 to near $1.47. The move was driven mainly by a dilutive $30 million equity offering and credit-agreement concerns, which outweighed a better-than-expected third-quarter earnings report.
TriSalus Life Sciences (TLSI) shares fell roughly 43% over the trailing 30 days, sliding from about $4.00 to approximately $2.28. The decline accelerated after third-quarter 2026 results were reported on November 10, 2026, when revenue of $12.9 million missed consensus estimates and management cut full-year guidance.
Beyond Air shares have traded in a volatile range around the $2–$3 level over the past month, with the trailing 30-day move roughly flat at approximately -5% despite sharp single-day swings around the company's quarterly report. The company reported record quarterly revenue of $2.3 million, up roughly 28% year over year, and reaffirmed its full-year revenue guidance.
AMIX shares fell roughly 51% over the last 30 days, closing near $1.48 after trading around $3.01 in mid-October. The decline extends a sustained multi-month downtrend, with the stock down approximately 78% over the last quarter.
Beyond Air (XAIR) is a commercial-stage medical device company focused on cylinder-free inhaled nitric oxide (NO) therapy; its LungFit PH system holds FDA approval and a CE Mark for neonatal hypoxic respiratory failure. Over the past 30 days, shares have declined roughly 8%, moving from about $2.19 to near $2.01 amid a sharp post-earnings reversal.
QTRX is trading down -2.65% during regular market hours, slipping from the prior close of $3.02 to $2.94 intraday. No verified news or fundamental catalyst found. The decline is likely continued post-earnings profit-taking, consistent with the stock's typical daily swing of roughly ±4%.
Electromed (ELMD) edged up +0.24% in regular trading, moving from a prior close of $24.96 to $25.02. No verified news or fundamental catalyst found; the move is consistent with quiet consolidation after the stock's -8.17% drop on Nov 11, its first reaction to Q1 FY2027 results reported Nov 10.
TXG dropped from a previous close of $62.05 to $58.41, a -5.87% decline during regular market hours. No verified news or fundamental catalyst found — the decline likely reflects continued post-earnings selling pressure and broad genomics-sector profit-taking, consistent with a stock that routinely swings 5% or more per session.
Upcoming catalysts: Regulatory submissions tied to post-traumatic stress disorder (PTSD) via the Wave Neuro distribution agreement, a planned FDA clearance pathway for an accelerated TMS (transcranial magnetic stimulation) system, and the rollout of a first-of-its-kind electronic health record integration are all in motion. Strategic positioning: The Greenbrook TMS acquisition has turned Neuronetics into a vertically integrated, device-plus-clinic platform, pairing its NeuroStar Advanced Therapy system with one of the largest interventional psychiatry clinic networks in the United States.
The central target of $6.00 is the arithmetic mean of four currently cited analyst price targets, which range from $5.00 to $7.00. STIM last traded near $1.62, so reaching $6.00 would require a gain of roughly 270% — an exceptionally large move.
Neuronetics (STIM) shares fell roughly 24% over the past 30 days, from about $2.13 on October 12, 2026, to $1.62 at the November 11 close. The decline was driven primarily by a dilutive $30 million underwritten public offering priced at $1.60 per share, alongside balance-sheet and going-concern concerns tied to the company's Perceptive credit facility.